Literature DB >> 24104750

The value of non-human primates in the development of monoclonal antibodies.

P J K van Meer1, M Kooijman, J W van der Laan, E H M Moors, H Schellekens.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24104750     DOI： 10.1038/nbt.2709

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  3 in total

1.  Experimental use of nonhuman primates is not a simple problem.

Authors:  Jarrod Bailey; Theodora Capaldo; Kathleen Conlee; Michelle Thew; John Pippin
Journal:  Nat Med       Date:  2008-10       Impact factor: 53.440

Review 2.  Preclinical safety testing of species-specific proteins produced with recombinant DNA-techniques. An attempt to transfer current experience into future testing strategies.

Authors:  K Teelmann; C Hohbach; H Lehmann
Journal:  Arch Toxicol       Date:  1986-12       Impact factor: 5.153

Review 3.  Angiogenesis in the corpus luteum.

Authors:  Hamish M Fraser; Christine Wulff
Journal:  Reprod Biol Endocrinol       Date:  2003-11-10       Impact factor: 5.211
  3 in total
  9 in total

1.  Image quality of Zr-89 PET imaging in the Siemens microPET Focus 220 preclinical scanner.

Authors:  Tyler J Bradshaw; Martin J Voorbach; David R Reuter; Anthony M Giamis; Sarah R Mudd; John D Beaver
Journal:  Mol Imaging Biol       Date:  2016-06       Impact factor: 3.488

Review 2.  Safety testing of monoclonal antibodies in non-human primates: Case studies highlighting their impact on human risk assessment.

Authors:  Frank R Brennan; Joy Cavagnaro; Kathleen McKeever; Patricia C Ryan; Melissa M Schutten; John Vahle; Gerhard F Weinbauer; Estelle Marrer-Berger; Lauren E Black
Journal:  MAbs       Date:  2017-10-26       Impact factor: 5.857

3.  Biosimilars entering the clinic without animal studies. A paradigm shift in the European Union.

Authors:  Leon A G J M van Aerts; Karen De Smet; Gabriele Reichmann; Jan Willem van der Laan; Christian K Schneider
Journal:  MAbs       Date:  2014       Impact factor: 5.857

Review 4.  Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.

Authors:  Kathryn Chapman; Akosua Adjei; Paul Baldrick; Antonio da Silva; Karen De Smet; Richard DiCicco; Seung Suh Hong; David Jones; Michael W Leach; James McBlane; Ian Ragan; Praveen Reddy; Donald I H Stewart; Amanda Suitters; Jennifer Sims
Journal:  MAbs       Date:  2016       Impact factor: 5.857

5.  An Evaluation of 20 Years of EU Framework Programme-Funded Immune-Mediated Inflammatory Translational Research in Non-Human Primates.

Authors:  Krista G Haanstra; Margreet Jonker; Bert A 't Hart
Journal:  Front Immunol       Date:  2016-11-07       Impact factor: 7.561

6.  Challenges and opportunities for the future of monoclonal antibody development: Improving safety assessment and reducing animal use.

Authors:  Fiona Sewell; Kathryn Chapman; Jessica Couch; Maggie Dempster; Shawn Heidel; Lise Loberg; Curtis Maier; Timothy K Maclachlan; Marque Todd; Jan Willem van der Laan
Journal:  MAbs       Date:  2017-05-05       Impact factor: 5.857

7.  A standardised framework to identify optimal animal models for efficacy assessment in drug development.

Authors:  Guilherme S Ferreira; Désirée H Veening-Griffioen; Wouter P C Boon; Ellen H M Moors; Christine C Gispen-de Wied; Huub Schellekens; Peter J K van Meer
Journal:  PLoS One       Date:  2019-06-13       Impact factor: 3.240

8.  Revision of ICH S8 Needed?

Authors:  Jan Willem Van Der Laan
Journal:  Front Toxicol       Date:  2022-04-25

Review 9.  Research Relevant Conditions and Pathology in Nonhuman Primates.

Authors:  Chandra Saravanan; Thierry Flandre; Carolyn L Hodo; Anne D Lewis; Lars Mecklenburg; Annette Romeike; Oliver C Turner; Hsi-Yu Yen
Journal:  ILAR J       Date:  2020-12-31       Impact factor: 1.521
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.